Kaigala G., VanDjinkin J., Taylor B.J., Backhouse C.J., Pilarski L.M.
University of Alberta, CA
Keywords: biomarkers, gene rearrangement, microchips, microfluidics, multiple myeloma
MM has a unique molecular signature and is well suited as a model system for performing analysis on microchips. MM multiplex genetic analysis for clonotypic signatures and genetic abnormalities offers the possibility for genetic profiling and monitoring. Analysis of ex-vivo cancer cells is performed in an automated, rapid, low-volume (nL) regime, leading to accelerated thermal kinetics by the use of a microfluidic platform. Both genomic DNA and IgH VDJ transcripts amplified from individual cells were detectable on-chip with 50pL of product, which accounts for 0.001% of the amplified product from one individual MM cell or from groups of MM cells. PCR on a chip with cDNA template from one single MM cell amplified the t(4;14) signature. Microfluidic platforms developed here employ novel technology for large scale genetic screening of MM patients, enabling predictions of risk and stratification for treatment, based on the genetic signature of each cancer.
Journal: TechConnect Briefs
Volume: 2, Technical Proceedings of the 2006 NSTI Nanotechnology Conference and Trade Show, Volume 2
Published: May 7, 2006
Pages: 49 - 52
Industry sectors: Advanced Materials & Manufacturing | Medical & Biotech
Topics: Biomaterials, Cancer Nanotechnology
ISBN: 0-9767985-7-3